Effect of winter sports on renal prognosis of patients with stage 3 chronic kidney disease

doi:10.3877/cma.j.issn.2095-3216.2021.01.007

Abstract

Abstract:

Objective

To explore the effect of winter sports on the renal prognosis of patients with chronic kidney disease (CKD) stage 3.

Methods

214 patients with CKD admitted to the First Affiliated Hospital of Hebei North University from February 2017 to April 2018 were prospectively selected as study subjects. Patients with CKD were divided into two groups according to their personal hobbies and wishes: sports group (winter sports, n=98) and non-sports group (non-winter sports, n=116). The renal prognosis of the two groups was compared, and the relationship between winter sports and renal prognosis of patients with CKD stage 3 was analyzed.

Results

After sports, the BUN, Scr, uric acid (UA) and urine albumin/creatinine ratio (UACR) levels of the sports group were lower than those of the non-sports group (P<0.05), and the eGFR level was higher than that of the non-sports group (P<0.05). The incidence of endpoint events in the sports group was lower than that of the non-sports group (P<0.05). The results of COX regression analysis showed that winter sports was an independent protective factor for the renal prognosis of patients with stage 3 CKD (OR: 0.384, 95%CI: 0.194-0.759, P<0.05).

Conclusion

Winter sports improved renal function and reduced the incidence of poor renal prognosis in patients with CKD stage 3.

Key words: Chronic kidney disease, Winter sports, Renal function, Prognosis

Xiaoli Han, Jiawei Wang, Linlin Wang, Zhifeng Wei, Shengjun Liu. Effect of winter sports on renal prognosis of patients with stage 3 chronic kidney disease[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2021, 10(01): 35-39.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2021.01.007

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2021/V10/I01/35

Figures/Tables 4

References 15

[1]	Barrett PM, Mccarthy FP, Evans M, et al. Hypertensive disorders of pregnancy and the risk of chronic kidney disease: a Swedish registry-based cohort study [J]. PLoS Med, 2020, 17(8): e1003255.
[2]	Eaton C, Comer M, Pruette C, et al. Text messaging adherence intervention for adolescents and young adults with chronic kidney disease: pilot randomized controlled trial and stakeholder interviews [J]. J Med Internet Res, 2020, 22(8): e19861.
[3]	Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey [J]. Lancet, 2012, 379(9818): 815-822.
[4]	邬碧波，唐琦，张黎明，等. 持续质量改进对慢性肾脏病3～4期患者肾功能预后的影响[J]. 第二军医大学学报，2018, 39(1): 6-12.
[5]	Andrassy KM. Comments on 'KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease’ [J]. Kidney Int, 2013, 84(3): 622-623.
[6]	Su HY, Yang C, Liang D, et al. Research advances in the mechanisms of hyperuricemia-induced renal injury [J]. Biomed Res Int, 2020, 2020: 5817348.
[7]	秦智，罗和生，肖国强. 5周亚低温状态游泳运动改善NAFLD大鼠的实验研究[J]. 河北体育学院学报，2013, 27(2): 77-82.
[8]	秦智，罗和生，肖国强. 亚低温状态5周游泳运动联合干预对NAFLD大鼠肝组织HSP70mRNA的影响[J]. 中国康复，2011, 26(5): 330-332.
[9]	肖国强，曹姣. 亚低温有氧运动与非酒精性脂肪肝防治：最新研究与思考[J]. 军事体育学报，2015, 34(4): 1-5.
[10]	上海慢性肾脏病早发现及规范化诊治与示范项目专家组. 慢性肾脏病筛查诊断及防治指南[J]. 中国实用内科杂志，2017, 37(1): 28-34.
[11]	Matyjek A, Literacki S, Niemczyk S, et al. Protein energy-wasting associated with nephrotic syndrome- the comparison of metabolic pattern in severe nephrosis to different stages of chronic kidney disease [J]. BMC Nephrol, 2020, 21(1): 346.
[12]	Satoh M, Hirose T, Nakayama S, et al. Blood pressure and chronic kidney disease stratified by gender and the use of antihypertensive drugs [J]. J Am Heart Assoc, 2020, 9(16): e015592.
[13]	Kattah AG, Garovic VD. Understanding sex differences in progression and prognosis of chronic kidney disease [J]. Ann Transl Med, 2020, 8(14): 897.
[14]	Hounkpatin HO, Harris S, Fraser S, et al. Prevalence of chronic kidney disease in adults in England: comparison of nationally representative cross-sectional surveys from 2003 to 2016 [J]. BMJ Open, 2020, 10(8): e038423.
[15]	张恒远，张燕林，周凌辉，等. 慢性肾脏病患者血清肿瘤坏死因子样弱凋亡诱导因子与疾病进展的相关性分析[J]. 华中科技大学学报(医学版), 2019, 48(5): 590-593.

项目		运动组(n＝98)	非运动组(n＝116)	t/χ²值	P值
年龄(岁)		47.12±6.77	46.24±6.84	0.943	0.347
男性[例(%)]		56(57.14)	60(51.72)	0.628	0.428
BMI(kg/m²)		25.67±4.09	25.22±4.42	0.782	0.435
吸烟史[例(%)]		35(35.71)	51(43.97)	1.505	0.220
糖尿病[例(%)]		20(20.41)	26(26.53)	0.127	0.722
高血压[例(%)]		77(78.57)	89(72.45)	0.104	0.747
原发疾病[例(%)]				1.281	0.865
	糖尿病肾病	20(20.41)	26(26.53)
	慢性肾小球肾炎	31(31.63)	32(27.59)
	高血压良性肾小动脉硬化症	21(21.43)	27(27.55)
	慢性肾盂肾炎	12(12.24)	18(15.52)
	痛风性肾病	14(14.29)	13(22.41)

项目		运动组(n＝98)	非运动组(n＝116)	t/χ²值	P值
年龄(岁)		47.12±6.77	46.24±6.84	0.943	0.347
男性[例(%)]		56(57.14)	60(51.72)	0.628	0.428
BMI(kg/m²)		25.67±4.09	25.22±4.42	0.782	0.435
吸烟史[例(%)]		35(35.71)	51(43.97)	1.505	0.220
糖尿病[例(%)]		20(20.41)	26(26.53)	0.127	0.722
高血压[例(%)]		77(78.57)	89(72.45)	0.104	0.747
原发疾病[例(%)]				1.281	0.865
	糖尿病肾病	20(20.41)	26(26.53)
	慢性肾小球肾炎	31(31.63)	32(27.59)
	高血压良性肾小动脉硬化症	21(21.43)	27(27.55)
	慢性肾盂肾炎	12(12.24)	18(15.52)
	痛风性肾病	14(14.29)	13(22.41)

分组	例数	BUN(mmol/L)		Scr(μmol/L)		UA(μmol/L)
分组	例数	干预前	干预后	干预前	干预后	干预前	干预后
非运动组	116	8.53±1.34	8.85±1.09^a	145.49±15.02	150.14±14.65^a	405.48±72.68	407.76±81.16
运动组	98	8.63±1.60	7.36±1.14^a	144.98±15.24	139.28±14.08^a	411.63±74.41	372.74±68.10^a
t值		0.512	9.745	0.247	5.503	0.609	3.382
P值		0.609	<0.001	0.805	<0.001	0.543	0.001
分组	例数	eGFR[ml/(min·1.73 m²)]		UACR(mg/g)
分组	例数	干预前	干预后	干预前	干预后
非运动组	116	40.88±7.51	34.38±9.13^a	561.57±75.86	556.76±64.25
运动组	98	41.01±5.50	38.41±8.69^a	556.15±77.95	452.39±69.59^a
t值		0.143	3.288	0.515	11.397
P值		0.886	0.001	0.607	<0.001

分组	例数	BUN(mmol/L)		Scr(μmol/L)		UA(μmol/L)
分组	例数	干预前	干预后	干预前	干预后	干预前	干预后
非运动组	116	8.53±1.34	8.85±1.09^a	145.49±15.02	150.14±14.65^a	405.48±72.68	407.76±81.16
运动组	98	8.63±1.60	7.36±1.14^a	144.98±15.24	139.28±14.08^a	411.63±74.41	372.74±68.10^a
t值		0.512	9.745	0.247	5.503	0.609	3.382
P值		0.609	<0.001	0.805	<0.001	0.543	0.001
分组	例数	eGFR[ml/(min·1.73 m²)]		UACR(mg/g)
分组	例数	干预前	干预后	干预前	干预后
非运动组	116	40.88±7.51	34.38±9.13^a	561.57±75.86	556.76±64.25
运动组	98	41.01±5.50	38.41±8.69^a	556.15±77.95	452.39±69.59^a
t值		0.143	3.288	0.515	11.397
P值		0.886	0.001	0.607	<0.001

变量	单因素		多因素
变量	HR(95%CI)	P值	HR(95%CI)	P值
年龄(岁)	0.997(0.954～1.042)	0.891
男性/女性(1/0)	1.077(0.592～1.960)	0.810
BMI(kg/m²)	0.991(0.923～1.064)	0.811
吸烟史(1/0)	1.667(0.920～3.023)	0.094	1.563(0.861～2.837)	0.144
原发病类型	1.052(0.839～1.318)	0.664
糖尿病(1/0)	0.819(0.381～1.758)	0.609
高血压(1/0)	0.908(0.437～1.887)	0.798
eGFR[ml/(min·1.73 m²)]	1.025(0.980～1.071)	0.283
BUN(mmol/L)	1.030(0.842～1.261)	0.774
Scr(μmol/L)	0.988(0.969～1.007)	0.209
UA(μmol/L)	1.003(0.999～1.007)	0.214
UACR(mg/g)	0.999(0.996～1.003)	0.738
冰雪运动(1/0)	0.371(0.188～0.734)	0.005	0.384(0.194～0.759)	0.006

Please choose a citation manager

Content to export